{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T13:25:59Z","timestamp":1762521959194,"version":"build-2065373602"},"reference-count":62,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2017,2,1]],"date-time":"2017-02-01T00:00:00Z","timestamp":1485907200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,2,1]],"date-time":"2017-02-01T00:00:00Z","timestamp":1485907200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Rheumatic Disease Clinics of North America"],"published-print":{"date-parts":[[2017,2]]},"DOI":"10.1016\/j.rdc.2016.09.009","type":"journal-article","created":{"date-parts":[[2016,11,25]],"date-time":"2016-11-25T03:04:54Z","timestamp":1480043094000},"page":"95-109","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":38,"title":["The Risk of Progressive Multifocal Leukoencephalopathy in the Biologic Era"],"prefix":"10.1016","volume":"43","author":[{"given":"Eamonn S.","family":"Molloy","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cassandra M.","family":"Calabrese","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leonard H.","family":"Calabrese","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.rdc.2016.09.009_bib1","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/S1474-4422(10)70040-5","article-title":"Progressive multifocal leukoencephalopathy and other disorders caused by JC virus: clinical features and pathogenesis","volume":"9","author":"Tan","year":"2010","journal-title":"Lancet Neurol"},{"issue":"9","key":"10.1016\/j.rdc.2016.09.009_bib2","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1007\/s00705-011-1008-x","article-title":"Taxonomical developments in the family Polyomaviridae","volume":"156","author":"Johne","year":"2011","journal-title":"Arch Virol"},{"issue":"4","key":"10.1016\/j.rdc.2016.09.009_bib3","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1002\/ana.24371","article-title":"Persistence and pathogenesis of the neurotropic polyomavirus JC","volume":"77","author":"Wollebo","year":"2015","journal-title":"Ann Neurol"},{"issue":"12","key":"10.1016\/j.rdc.2016.09.009_bib4","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1038\/nrneurol.2010.164","article-title":"Progressive multifocal leukoencephalopathy and other forms of JC virus disease","volume":"6","author":"Brew","year":"2010","journal-title":"Nat Rev Neurol"},{"issue":"5","key":"10.1016\/j.rdc.2016.09.009_bib5","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1093\/infdis\/jiq097","article-title":"Pathogenesis of progressive multifocal leukoencephalopathy\u2013revisited","volume":"203","author":"White","year":"2011","journal-title":"J\u00a0Infect Dis"},{"issue":"4","key":"10.1016\/j.rdc.2016.09.009_bib6","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1097\/PAT.0b013e3283463558","article-title":"Immunosuppression increases latent infection of brain by JC polyomavirus","volume":"43","author":"Bayliss","year":"2011","journal-title":"Pathology"},{"issue":"1","key":"10.1016\/j.rdc.2016.09.009_bib7","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1093\/infdis\/jis668","article-title":"Immunosuppression increases JC polyomavirus large T antigen DNA load in the brains of patients without progressive multifocal leukoencephalopathy","volume":"207","author":"Bayliss","year":"2013","journal-title":"J\u00a0Infect Dis"},{"issue":"67","key":"10.1016\/j.rdc.2016.09.009_bib8","first-page":"495","article-title":"The pathogenesis of progressive multifocal leukoencephalopathy","volume":"12","author":"Berger","year":"2011","journal-title":"Discov Med"},{"issue":"3","key":"10.1016\/j.rdc.2016.09.009_bib9","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1136\/jnnp.2009.187666","article-title":"Progressive multifocal leukoencephalopathy in individuals with minimal or occult immunosuppression","volume":"81","author":"Gheuens","year":"2010","journal-title":"J\u00a0Neurol Neurosurg Psychiatry"},{"issue":"3","key":"10.1016\/j.rdc.2016.09.009_bib10","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1212\/WNL.0b013e318225ab3f","article-title":"Progressive multifocal leukoencephalopathy in a patient without immunodeficiency","volume":"77","author":"Tan","year":"2011","journal-title":"Neurology"},{"issue":"7","key":"10.1016\/j.rdc.2016.09.009_bib11","doi-asserted-by":"crossref","first-page":"2116","DOI":"10.1002\/art.22657","article-title":"Progressive multifocal leukoencephalopathy in rheumatic diseases: evolving clinical and pathologic patterns of disease","volume":"56","author":"Calabrese","year":"2007","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.rdc.2016.09.009_bib12","first-page":"S369","article-title":"Progressive multifocal leukoencephalopathy associated with biologic therapy in rheumatic diseases: strengthening association with rituximab","volume":"66","author":"Molloy","year":"2014","journal-title":"Arthritis Rheumatol"},{"issue":"2","key":"10.1016\/j.rdc.2016.09.009_bib13","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1038\/nrrheum.2014.167","article-title":"Sorting out the risks in progressive multifocal leukoencephalopathy","volume":"11","author":"Calabrese","year":"2015","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.rdc.2016.09.009_bib14","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1146\/annurev.med.080708.082655","article-title":"Progressive multifocal leukoencephalopathy in patients on immunomodulatory therapies","volume":"61","author":"Major","year":"2010","journal-title":"Annu Rev Med"},{"key":"10.1016\/j.rdc.2016.09.009_bib15","doi-asserted-by":"crossref","first-page":"241","DOI":"10.3389\/fimmu.2015.00241","article-title":"B\u00a0cells and progressive multifocal leukoencephalopathy: search for the missing link","volume":"6","author":"Durali","year":"2015","journal-title":"Front Immunol"},{"issue":"3","key":"10.1016\/j.rdc.2016.09.009_bib16","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1002\/ana.22128","article-title":"Anti-JC virus antibodies: implications for PML risk stratification","volume":"68","author":"Gorelik","year":"2010","journal-title":"Ann Neurol"},{"issue":"3","key":"10.1016\/j.rdc.2016.09.009_bib17","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1097\/WCO.0000000000000200","article-title":"Neurological immune reconstitution inflammatory response: riding the tide of immune recovery","volume":"28","author":"Clifford","year":"2015","journal-title":"Curr Opin Neurol"},{"issue":"3","key":"10.1016\/j.rdc.2016.09.009_bib18","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1097\/WCO.0b013e328346d2a3","article-title":"The basis for modeling progressive multifocal leukoencephalopathy pathogenesis","volume":"24","author":"Berger","year":"2011","journal-title":"Curr Opin Neurol"},{"issue":"2","key":"10.1016\/j.rdc.2016.09.009_bib19","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1212\/01.wnl.0000194227.16696.11","article-title":"Seizures and their outcome in progressive multifocal leukoencephalopathy","volume":"66","author":"Lima","year":"2006","journal-title":"Neurology"},{"issue":"8","key":"10.1016\/j.rdc.2016.09.009_bib20","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1111\/j.1468-1331.2006.01362.x","article-title":"Progressive multifocal leukoencephalopathy: value of diffusion-weighted and contrast-enhanced magnetic resonance imaging for diagnosis and treatment control","volume":"13","author":"K\u00fcker","year":"2006","journal-title":"Eur J Neurol"},{"issue":"1","key":"10.1016\/j.rdc.2016.09.009_bib21","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1080\/13550280590900742","article-title":"Atypical radiological presentation of progressive multifocal leukoencephalopathy following liver transplantation","volume":"11","author":"Lima","year":"2005","journal-title":"J\u00a0Neurovirol"},{"issue":"3","key":"10.1016\/j.rdc.2016.09.009_bib22","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1212\/WNL.52.3.657","article-title":"Progressive multifocal leukoencephalopathy: unusual MRI findings and prolonged survival in a pregnant woman","volume":"52","author":"Rosas","year":"1999","journal-title":"Neurology"},{"issue":"10","key":"10.1016\/j.rdc.2016.09.009_bib23","first-page":"1896","article-title":"Progressive multifocal leukoencephalopathy in AIDS: are there any MR findings useful to patient management and predictive of patient survival? AIDS Clinical Trials Group, 243 Team","volume":"20","author":"Post","year":"1999","journal-title":"AJNR Am J Neuroradiol"},{"issue":"1","key":"10.1016\/j.rdc.2016.09.009_bib24","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1002\/ana.21085","article-title":"Inflammatory progressive multifocal leukoencephalopathy in human immunodeficiency virus-negative patients","volume":"62","author":"Huang","year":"2007","journal-title":"Ann Neurol"},{"issue":"9","key":"10.1016\/j.rdc.2016.09.009_bib25","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1097\/00002030-199610090-00004","article-title":"Polymerase chain reaction on cerebrospinal fluid for diagnosis of virus-associated opportunistic diseases of the central nervous system in HIV-infected patients","volume":"10","author":"Cinque","year":"1996","journal-title":"AIDS"},{"issue":"12","key":"10.1016\/j.rdc.2016.09.009_bib26","doi-asserted-by":"crossref","first-page":"2452","DOI":"10.1212\/01.WNL.0000148585.41802.6C","article-title":"Fatal inflammatory AIDS-associated PML with high CD4 counts on HAART: a new clinical entity?","volume":"63","author":"Di Giambenedetto","year":"2004","journal-title":"Neurology"},{"issue":"9","key":"10.1016\/j.rdc.2016.09.009_bib27","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1212\/01.wnl.0000242728.26433.12","article-title":"Immune reconstitution inflammatory syndrome associated with PML in AIDS: a treatable disorder","volume":"67","author":"Martinez","year":"2006","journal-title":"Neurology"},{"issue":"4","key":"10.1016\/j.rdc.2016.09.009_bib28","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1056\/NEJMoa051847","article-title":"Progressive multifocal leukoencephalopathy in a patient treated with natalizumab","volume":"353","author":"Langer-Gould","year":"2005","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"10.1016\/j.rdc.2016.09.009_bib29","first-page":"66","article-title":"Possible pitfalls in the diagnostic of progressive multifocal leukoencephalopathy","volume":"35","author":"Zivanovic","year":"2016","journal-title":"Clin Neuropathol"},{"issue":"S10","key":"10.1016\/j.rdc.2016.09.009_bib30","first-page":"130","article-title":"Rheumatologists knowledge, attitudes and concerns regarding progressive multifocal leukoencephalopathy","volume":"60","author":"Calabrese","year":"2009","journal-title":"Arthritis Rheum"},{"issue":"11","key":"10.1016\/j.rdc.2016.09.009_bib31","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1177\/0961203308089445","article-title":"Progressive multifocal leukoencephalopathy\u2014the importance of early diagnosis illustrated in four cases","volume":"17","author":"Nived","year":"2008","journal-title":"Lupus"},{"issue":"1","key":"10.1016\/j.rdc.2016.09.009_bib32","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1148\/radiology.182.1.1727311","article-title":"Cerebral vasculitis: MR imaging and angiographic correlation","volume":"182","author":"Greenan","year":"1992","journal-title":"Radiology"},{"issue":"2","key":"10.1016\/j.rdc.2016.09.009_bib33","first-page":"317","article-title":"Diagnosing intracranial vasculitis: the roles of MR and angiography","volume":"15","author":"Harris","year":"1994","journal-title":"AJNR Am J Neuroradiol"},{"issue":"6","key":"10.1016\/j.rdc.2016.09.009_bib34","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1212\/WNL.49.6.1696","article-title":"Idiopathic granulomatous angiitis of the CNS manifesting as diffuse white matter disease","volume":"49","author":"Finelli","year":"1997","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.rdc.2016.09.009_bib35","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.semarthrit.2009.08.005","article-title":"Magnetic resonance imaging and brain histopathology in neuropsychiatric systemic lupus erythematosus","volume":"40","author":"Sibbitt","year":"2010","journal-title":"Semin Arthritis Rheum"},{"issue":"2","key":"10.1016\/j.rdc.2016.09.009_bib36","first-page":"3","article-title":"Rituxan warning","volume":"41","year":"2007","journal-title":"FDA Consum"},{"issue":"12","key":"10.1016\/j.rdc.2016.09.009_bib37","doi-asserted-by":"crossref","first-page":"3761","DOI":"10.1002\/art.24966","article-title":"Progressive multifocal leukoencephalopathy: a national estimate of frequency in systemic lupus erythematosus and other rheumatic diseases","volume":"60","author":"Molloy","year":"2009","journal-title":"Arthritis Rheum"},{"issue":"1","key":"10.1016\/j.rdc.2016.09.009_bib38","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1086\/314830","article-title":"BK and JC viruses in patients with systemic lupus erythematosus: prevalent and persistent BK viruria, sequence stability of the viral regulatory regions, and nondetectable viremia","volume":"180","author":"Sundsfjord","year":"1999","journal-title":"J\u00a0Infect Dis"},{"issue":"3","key":"10.1016\/j.rdc.2016.09.009_bib39","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1177\/0961203312470977","article-title":"Analysis of JC virus DNA in NPSLE patients treated with different immunomodulatory agents","volume":"22","author":"Iacobaeus","year":"2013","journal-title":"Lupus"},{"issue":"Pt 11","key":"10.1016\/j.rdc.2016.09.009_bib40","doi-asserted-by":"crossref","first-page":"2625","DOI":"10.1099\/0022-1317-81-11-2625","article-title":"VP1 DNA sequences of JC and BK viruses detected in urine of systemic lupus erythematosus patients reveal no differences from strains expressed in normal individuals","volume":"81","author":"Bendiksen","year":"2000","journal-title":"J\u00a0Gen Virol"},{"issue":"8","key":"10.1016\/j.rdc.2016.09.009_bib41","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1038\/nrrheum.2009.142","article-title":"Therapy: targeted but not trouble-free: efalizumab and PML","volume":"5","author":"Molloy","year":"2009","journal-title":"Nat Rev Rheumatol"},{"issue":"20","key":"10.1016\/j.rdc.2016.09.009_bib42","doi-asserted-by":"crossref","first-page":"4834","DOI":"10.1182\/blood-2008-10-186999","article-title":"Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project","volume":"113","author":"Carson","year":"2009","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.rdc.2016.09.009_bib43","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1634\/theoncologist.2010-0098","article-title":"Inclusion of rituximab in treatment protocols for non-Hodgkin\u2019s lymphomas and risk for progressive multifocal leukoencephalopathy","volume":"15","author":"Tuccori","year":"2010","journal-title":"Oncologist"},{"issue":"11","key":"10.1016\/j.rdc.2016.09.009_bib44","doi-asserted-by":"crossref","first-page":"3225","DOI":"10.1002\/art.24906","article-title":"Progressive multifocal leukoencephalopathy following rituximab treatment in a patient with rheumatoid arthritis","volume":"60","author":"Fleischmann","year":"2009","journal-title":"Arthritis Rheum"},{"issue":"9","key":"10.1016\/j.rdc.2016.09.009_bib45","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1001\/archneurol.2011.103","article-title":"Rituximab-associated progressive multifocal leukoencephalopathy in rheumatoid arthritis","volume":"68","author":"Clifford","year":"2011","journal-title":"Arch Neurol"},{"issue":"9","key":"10.1016\/j.rdc.2016.09.009_bib46","doi-asserted-by":"crossref","first-page":"3043","DOI":"10.1002\/art.34468","article-title":"Progressive multifocal leukoencephalopathy associated with immunosuppressive therapy in rheumatic diseases: evolving role of biologic therapies","volume":"64","author":"Molloy","year":"2012","journal-title":"Arthritis Rheum"},{"issue":"5","key":"10.1016\/j.rdc.2016.09.009_bib47","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1080\/13550280802348222","article-title":"The bone marrow, B cells, and JC virus","volume":"14","author":"Houff","year":"2008","journal-title":"J\u00a0Neurovirol"},{"issue":"7","key":"10.1016\/j.rdc.2016.09.009_bib48","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1177\/0961203314524292","article-title":"A\u00a0case of progressive multifocal leukoencephalopathy in a lupus patient treated with belimumab","volume":"23","author":"Fredericks","year":"2014","journal-title":"Lupus"},{"issue":"3","key":"10.1016\/j.rdc.2016.09.009_bib49","doi-asserted-by":"crossref","first-page":"551","DOI":"10.3899\/jrheum.140577","article-title":"Progressive multifocal leukoencephalopathy associated with belimumab in a patient with systemic lupus erythematosus","volume":"42","author":"Leblanc-Trudeau","year":"2015","journal-title":"J\u00a0Rheumatol"},{"issue":"7","key":"10.1016\/j.rdc.2016.09.009_bib50","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1136\/annrheumdis-2013-204978","article-title":"A\u00a0case report of progressive multifocal leucoencephalopathy (PML) associated with adalimumab","volume":"73","author":"Ray","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.rdc.2016.09.009_bib51","first-page":"643216","article-title":"JC virus PCR detection is not infallible: a fulminant case of progressive multifocal leukoencephalopathy with false-negative cerebrospinal fluid studies despite progressive clinical course and radiological findings","volume":"2015","author":"Babi","year":"2015","journal-title":"Case Rep Neurol Med"},{"key":"10.1016\/j.rdc.2016.09.009_bib52","unstructured":"Communication About an Ongoing Safety Review of CellCept (mycophenolate mofetil) and Myfortic (mycophenolic acid). U.S Food and Drug Administration. MedWatch. The FDA Safety Information and Adverse Event Reporting Program. 2009. Available at: http:\/\/www.fda.gov\/Drugs\/DrugSafety\/PostmarketDrugSafetyInformationforPatientsandProviders\/DrugSafetyInformationforHeathcareProfessionals\/ucm072438.htm. Accessed June 28, 2011."},{"issue":"10","key":"10.1016\/j.rdc.2016.09.009_bib53","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1097\/TP.0b013e31818b62c8","article-title":"Progressive multifocal leukoencephalopathy and use of mycophenolate mofetil after kidney transplantation","volume":"86","author":"Neff","year":"2008","journal-title":"Transplantation"},{"issue":"1","key":"10.1016\/j.rdc.2016.09.009_bib54","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.jcv.2011.10.003","article-title":"Multi-site analytical validation of an assay to detect anti-JCV antibodies in human serum and plasma","volume":"53","author":"Plavina","year":"2012","journal-title":"J\u00a0Clin Virol"},{"issue":"1","key":"10.1016\/j.rdc.2016.09.009_bib55","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1002\/ana.23893","article-title":"JC virus antibody status underestimates infection rates","volume":"74","author":"Berger","year":"2013","journal-title":"Ann Neurol"},{"issue":"6","key":"10.1016\/j.rdc.2016.09.009_bib56","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1007\/s13365-014-0289-8","article-title":"Progressive multifocal leukoencephalopathy therapy","volume":"21","author":"Clifford","year":"2015","journal-title":"J\u00a0Neurovirol"},{"issue":"4","key":"10.1016\/j.rdc.2016.09.009_bib57","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1007\/s13365-013-0173-y","article-title":"A\u00a0study of mefloquine treatment for progressive multifocal leukoencephalopathy: results and exploration of predictors of PML outcomes","volume":"19","author":"Clifford","year":"2013","journal-title":"J\u00a0Neurovirol"},{"issue":"3","key":"10.1016\/j.rdc.2016.09.009_bib58","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1177\/1756285615621029","article-title":"Use of interleukin-2 for management of natalizumab-associated progressive multifocal leukoencephalopathy: case report and review of literature","volume":"9","author":"Dubey","year":"2016","journal-title":"Ther Adv Neurol Disord"},{"issue":"11","key":"10.1016\/j.rdc.2016.09.009_bib59","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1093\/cid\/ciu682","article-title":"Treating progressive multifocal leukoencephalopathy with interleukin 7 and vaccination with JC virus capsid protein VP1","volume":"59","author":"Sospedra","year":"2014","journal-title":"Clin Infect Dis"},{"issue":"2","key":"10.1016\/j.rdc.2016.09.009_bib60","doi-asserted-by":"crossref","first-page":"e213","DOI":"10.1212\/NXI.0000000000000213","article-title":"Interleukin-7 treatment of PML in a patient with idiopathic lymphocytopenia","volume":"3","author":"Miskin","year":"2016","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"9","key":"10.1016\/j.rdc.2016.09.009_bib61","doi-asserted-by":"crossref","first-page":"e0136046","DOI":"10.1371\/journal.pone.0136046","article-title":"CRISPR\/Cas9 system as an agent for eliminating polyomavirus JC infection","volume":"10","author":"Wollebo","year":"2015","journal-title":"PLoS One"},{"issue":"3","key":"10.1016\/j.rdc.2016.09.009_bib62","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1007\/s13311-016-0439-1","article-title":"Gene editing for treatment of neurological infections","volume":"13","author":"White","year":"2016","journal-title":"Neurotherapeutics"}],"container-title":["Rheumatic Disease Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889857X16300606?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889857X16300606?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T11:15:47Z","timestamp":1760181347000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889857X16300606"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,2]]},"references-count":62,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,2]]}},"alternative-id":["S0889857X16300606"],"URL":"https:\/\/doi.org\/10.1016\/j.rdc.2016.09.009","relation":{},"ISSN":["0889-857X"],"issn-type":[{"type":"print","value":"0889-857X"}],"subject":[],"published":{"date-parts":[[2017,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Risk of Progressive Multifocal Leukoencephalopathy in the Biologic Era","name":"articletitle","label":"Article Title"},{"value":"Rheumatic Disease Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rdc.2016.09.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}